Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 5, 2024Annals of HematologyOpen Access

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

View Full Paper
Ask AI
Bookmark
Share

Authors

SISusanne IsfortNBNikolas von BubnoffHAHaifa Kathrin Al‐Ali

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Isfort et al. (2024) studied this question.

synapsesocial.com/papers/68e613bcb6db6435875a64cdhttps://doi.org/10.1007/s00277-024-05867-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia2025 · 2 citations
  2. 2Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors2026
  3. 3Comparative efficacy and safety of JAK inhibitor-based strategies in JAK inhibitor-naïve myelofibrosis: A systematic review and network meta-analysis2026
  4. 4Disrupting a new NFkB-IL-6-JAK2-STAT cascade with novel NFkB inhibitors reduces primary myelofibrosis growth2025
  5. 5Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib2024